Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature.
Adam StrzelczykJanina GrauThomas BastAstrid BertscheUlrich BettendorfAndreas HahnHans HartmannChristoph HertzbergFrauke HornemannIlka ImmischJulia JacobsKerstin A KlotzGerhard KlugerSusanne KnakeMarkus KnufGerhard KurlemannKlaus MarquardThomas MayerSascha MeyerHiltrud MuhleKaren Müller-SchlüterFelix von PodewilsFelix RosenowSusanne RufMatthias SauterHannah SchäferJan-Ulrich SchlumpSusanne Schubert-BastSteffen SyrbeCharlotte ThielsRegina TrollmannAdelheid Wiemer-KruelBernd WilkenBianca ZukunftJohann Philipp ZöllnerPublished in: Expert review of clinical pharmacology (2021)
The selection of ASDs for patients with TSC-associated epilepsy follows well-evaluated recommendations, including the guidelines regarding vigabatrin use in children. Several characteristics, such as the comparatively high frequency of valproate use and polytherapy, reflect the severity of TSC-associated epilepsy.